Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575440 · ClinicalTrials.gov registry record
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
A clinical trial of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT05575440 is a study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants, above the 21-participant average among 3 other Thyroid Gland Papillary Carcinoma trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05575440, a study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- OTHER Survey Administration
- RADIATION Fluorine F 18 Tetrafluoroborate
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2028-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05575440
The ClinicalTrials.gov registry entry for NCT05575440 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 21-participant average among 3 other Thyroid Gland Papillary Carcinoma trials with a reported enrollment target (14% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thyroid Gland Papillary Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT05575440 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05575440 about?
NCT05575440 is a clinical study titled "Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer". This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 1...
What is the current status of trial NCT05575440?
This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2022-04-22. Estimated completion is 2028-05-01.
What conditions does trial NCT05575440 study?
This clinical trial studies the following conditions: Thyroid Gland Papillary Carcinoma, Thyroid Gland Follicular Carcinoma, Differentiated Thyroid Gland Carcinoma.
What interventions are being tested in trial NCT05575440?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Survey Administration (OTHER), Fluorine F 18 Tetrafluoroborate (RADIATION).
Who is sponsoring clinical trial NCT05575440?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05575440 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Gland Papillary Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
RECRUITING · Phase 2
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Thyroid Gland Papillary Carcinoma
All registered trials for this condition
Thyroid Gland Follicular Carcinoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.